Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia

Preeclampsia Postpartum Clinical Trial

Official title: Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia

Status Recruiting

Clinical Trial Summary

Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that occurs during the preeclamptic pregnancy and persists postpartum, despite the remission of clinical symptoms. The purpose of this investigation is to determine the mechanisms contributing to this lasting blood vessel damage caused by reduced endothelial function in women who have had preeclampsia compared to women who had a healthy pregnancy. Identification of these mechanisms and treatment strategies may lead to better clinical management of cardiovascular disease risk in these women. The purpose of this study is to examine the microvascular differences in women who have had preeclampsia following activation of protective angiotensin receptors in the skin. This will help increase understanding of the mechanisms of angiotensin II receptors in these women, and how activation of these receptors may restore microvascular function. In this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) the investigators examine the blood vessels in a dime-sized area of the skin.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Pre-Eclampsia
• Preeclampsia Postpartum

• NCT number: NCT05937841
• Study type: Interventional
• Source: University of Iowa
• Contact: Kelsey Schwartz
• Phone: 319-467-3096
• Email: kelsey-schwartz@uiowa.edu
• Status: Recruiting
• Phase: Early Phase 1
• Start date: June 28, 2023
• Completion date: June 1, 2025